🧬 Gene & Cell Therapy Weekly Update: Parkinson’s FDA clearance, $1.3B Heart Disease Acquisition & More!
In this episode of Gene and Cell Therapy Updates, we cover the latest advances shaping the future of medicine. Whether you’re tracking CAR T-cell innovations, gene editing, or early access programs, this update has you covered. 👨⚕️💡
🧠 Capsida gets FDA IND clearance for Parkinson’s gene therapy targeting GBA mutations
⚠️ Sarepta pauses ELEVIDYS after two fatal liver failure cases in non-ambulatory patients
💪 NurOwn shows 90% five-year survival in ALS patients
🦴 BioRestorative’s BRTX-100 cuts pain and improves function in chronic lumbar disc disease
🧬 Hemophilia B gene therapy validated with 13-year safety and efficacy data
💉 J&J’s CAR T achieves 80% complete response in large B-cell lymphoma
🧪 Keymed’s CM336 shows success in autoimmune hemolytic anemia, published in NEJM
🔁 AbelZeta’s C-CAR039 delivers 85% complete response and long-term remission in B-NHL
🛡️ Breyanzi hits over 95 percent ORR in marginal zone lymphoma
🔬 Lyell’s LYL314 shows 72% CR in advanced LBCL with outpatient-friendly profile
🧫 ACCESS Trial proves mismatched donors expand transplant access with low GVHD
🧑⚕️ LUMEVOQ advances to French early access program for LHON
👁️ Ocugen launches Phase 2/3 for Stargardt disease gene therapy
❤️ Lilly acquires Verve Therapeutics in $1.3B deal to pioneer one-time cardiovascular gene therapies
This isn’t just biotech news—it’s a roadmap to what’s next in precision medicine and patient care. 🎯
📢 Stay Ahead in Gene & Cell Therapy Research!
✅ Like, share, and subscribe for weekly updates on gene and cell therapy advancements
#GeneTherapy #CellTherapy #CAR_T #ALS #HemophiliaB #StargardtDisease #ParkinsonsDisease #LHON #BcellLymphoma #OncologyResearch #BiotechUpdates #PharmaNews #LucidQuest #LQVentures #PrecisionMedicine #RareDisease #GeneEditing